CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 35 target
Drug / intervention
Camrelizumab +4 moredrug
Likely dose
Not stated in record
Key inclusion· 9
  • ✓Newly diagnosed breast cancer
  • ✓Ages 18-75, female
  • ✓Early or locally advanced TNBC with absent HER2, ER, PR expression
  • ✓Tumor stage II-III
Key exclusion· 26
  • ✕Stage IV (metastatic) or bilateral breast cancer
  • ✕Inflammatory breast cancer
  • ✕Prior anti-tumor therapy within 12 months (chemotherapy, targeted, radiation, immunotherapy, biotherapy, TAE)
  • ✕History of invasive malignancy ≤5 years prior except basal/squamous cell skin or in situ cervical cancer

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05447702
NCT05447702Phase 2RecruitingUpdate OverdueUpdated 37mo ago · Completion was 30mo ago
Enrollment Stalled
Long Recruiting
Update Overdue
CompareCT.gov

A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)

West China Hospital·interventional·Posted Jul 7, 2022·Updated May 22, 2023

In Brief

A Phase 2 clinical trial evaluating Camrelizumab, Apatinib, and 3 other interventions for Triple Negative Breast Cancer. Currently recruiting, targeting 35 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple Negative Breast Cancer
CountriesChina
CollaboratorsJiangsu HengRui Medicine Co., Ltd.

Timeline

Phase 2Recruiting
20232024202520262027
First PostedJul 7, 2022
Enrollment StartNov 1, 2022
Primary CompletionDec 31, 2023
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.0 years ago

Interventions

Camrelizumabdrug

Intravenous (IV) infusion

Apatinibdrug

po.

Nab-paclitaxeldrug

IV infusion.

Epirubicindrug

IV infusion.

Cyclophosphamidedrug

IV infusion.